CYRX:NASDAQCryoPort, Inc. Analysis
Data as of 2026-03-28 - not real-time
$7.82
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Cryoport’s share price is currently trading below its short‑term and long‑term moving averages, placing the stock in a bearish technical zone, while the RSI hovers near the neutral threshold and the MACD histogram has just turned positive, hinting at a potential short‑term bounce. The price sits just above the identified support level and well under the resistance ceiling, with volume trending downward and beta above one, underscoring heightened systematic risk and elevated 30‑day volatility.
Fundamentally, the company posted solid revenue growth and a healthy gross margin, yet operating results remain marginally negative and earnings per share are still in the loss region. A robust cash pile dwarfs its debt load, the price‑to‑book ratio is comfortably below one and analysts collectively assign a strong‑buy rating with a median target substantially higher than the current market price, suggesting significant upside potential.
Fundamentally, the company posted solid revenue growth and a healthy gross margin, yet operating results remain marginally negative and earnings per share are still in the loss region. A robust cash pile dwarfs its debt load, the price‑to‑book ratio is comfortably below one and analysts collectively assign a strong‑buy rating with a median target substantially higher than the current market price, suggesting significant upside potential.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price near technical support with bearish trend bias
- decreasing volume indicating limited short‑term buying pressure
- recent earnings beat on revenue but missed EPS expectations
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- management guidance pointing to higher revenue in the next fiscal year
- strong cash position relative to debt and a price‑to‑book discount
- analyst consensus of strong‑buy and sizable upside relative to current price
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- secular demand growth for temperature‑controlled logistics in cell‑therapy and biopharma
- sustainable balance sheet with ample liquidity for strategic investments
- valuation metrics indicating a discount to intrinsic value despite negative earnings
Key Metrics & Analysis
Financial Health
Revenue Growth9.60%
Profit Margin44.45%
P/E Ratio-12.2
ROE-7.51%
ROA-2.69%
Debt/Equity45.90
P/B Ratio0.8
Op. Cash Flow$-8580000
Free Cash Flow$-396125
Industry P/E28.1
Technical Analysis
TrendBearish
RSI40.8
Support$7.61
Resistance$9.36
MA 20$8.15
MA 50$8.83
MA 200$8.84
MACDBullish
VolumeDecreasing
Fear & Greed Index65.98
Valuation
Target Price$13.44
Upside/Downside71.84%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.31
Volatility42.32%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.